Sai Parenterals Limited (SAIPARENT) Q2 FY27 results show revenue up 9% QoQ, PAT grows 32.7% QoQ, ahead of FY27 targets.
Sai Parenterals Limited (SAIPARENT) acquires 60% stake in Prathyak Laboratories for Rs. 15 crore, enhancing its R&D capabilities.
Sai Parenterals Limited renews AUD 30 million OTC supply agreement with Australian pharmacy chain, expanding product portfolio and agreement tenure.
Sai Parenterals Limited's Australian subsidiary, Noumed Pharmaceuticals, renews its exclusive OTC supply agreement with Australia's leading pharmacy networks.